Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seiji Yano

Showing results (81-90 of 286) with videos related to

Pageof 29
Sort By:
Oncotarget|June 23, 2014
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cellsAzusa Tanimoto, Tadaaki Yamada, Shigeki Nanjo, et al.
Oncology Letters|November 4, 2014
Distinct allelic expression patterns of imprinted <i>IGF2</i> in adenocarcinoma and squamous cell carcinoma of the lungSatoru Ozaki, Ei Kawahara, Shiori Maenaka, et al.
International Cancer Conference Journal|June 1, 2019
A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinibHironori Kitade, Koushiro Ohtsubo, Kengo Hokkoku, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2016
Histone Deacetylase 3 Inhibition Overcomes <i>BIM</i> Deletion Polymorphism-Mediated Osimertinib Resistance in <i>EGFR-</i>Mutant Lung CancerAzusa Tanimoto, Shinji Takeuchi, Sachiko Arai, et al.
Journal of Pharmacological Sciences|September 16, 2006
The novel Src kinase inhibitor M475271 inhibits VEGF-induced vascular endothelial-cadherin and beta-catenin phosphorylation but increases their associationNermin Ali, Masanori Yoshizumi, Seiji Yano, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 17, 2002
Oral UFT (uracil plus futrafur) for neoadjuvant chemotherapy of gastric cancerYoshinori Nio, Chikage Iguchi, Kunihiro Yamasawa, et al.
Cancer Science|August 1, 2020
MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinibAkihiro Nishiyama, Shinji Takeuchi, Yuta Adachi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2010
[Combined chemotherapy with cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma]Tadaaki Yamada, Hisatsugu Mouri, Kouji Izumi, et al.
Cancer Science|June 19, 2021
Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancerKoji Fukuda, Sakiko Otani, Shinji Takeuchi, et al.
International Journal of Cancer|January 16, 2013
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factorTakako Sano, Shinji Takeuchi, Takayuki Nakagawa, et al.
Pageof 29

Showing results (81-90 of 286) with videos related to

Sort By:
Pageof 29
Oncotarget|June 23, 2014
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cellsAzusa Tanimoto, Tadaaki Yamada, Shigeki Nanjo, et al.
Oncology Letters|November 4, 2014
Distinct allelic expression patterns of imprinted <i>IGF2</i> in adenocarcinoma and squamous cell carcinoma of the lungSatoru Ozaki, Ei Kawahara, Shiori Maenaka, et al.
International Cancer Conference Journal|June 1, 2019
A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinibHironori Kitade, Koushiro Ohtsubo, Kengo Hokkoku, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2016
Histone Deacetylase 3 Inhibition Overcomes <i>BIM</i> Deletion Polymorphism-Mediated Osimertinib Resistance in <i>EGFR-</i>Mutant Lung CancerAzusa Tanimoto, Shinji Takeuchi, Sachiko Arai, et al.
Journal of Pharmacological Sciences|September 16, 2006
The novel Src kinase inhibitor M475271 inhibits VEGF-induced vascular endothelial-cadherin and beta-catenin phosphorylation but increases their associationNermin Ali, Masanori Yoshizumi, Seiji Yano, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 17, 2002
Oral UFT (uracil plus futrafur) for neoadjuvant chemotherapy of gastric cancerYoshinori Nio, Chikage Iguchi, Kunihiro Yamasawa, et al.
Cancer Science|August 1, 2020
MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinibAkihiro Nishiyama, Shinji Takeuchi, Yuta Adachi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2010
[Combined chemotherapy with cisplatin plus vinorelbine showed efficacy in a case of metastatic primary cutaneous adenoid cystic carcinoma]Tadaaki Yamada, Hisatsugu Mouri, Kouji Izumi, et al.
Cancer Science|June 19, 2021
Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancerKoji Fukuda, Sakiko Otani, Shinji Takeuchi, et al.
International Journal of Cancer|January 16, 2013
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factorTakako Sano, Shinji Takeuchi, Takayuki Nakagawa, et al.
Pageof 29